UND campus in shock after recently retired Provost Tom DiLorenzo is killed in South Carolina robbery, arrests made – Grand Forks Herald

DiLorenzo was with his wife, Suzanne Austin, the College of Charlestons new appointed provost, at approximately 6:15 a.m. when two men armed with a handgun demanded money from the couple in downtown Charleston.

DiLorenzo was shot during the robbery attempt and was taken to a local hospital, where he died, according to a police report. Austin wasnt injured.

The investigation is ongoing.

Late Friday night, Charleston Police announced the arrests of two juvenile males. The suspects, ages 15 and 16, have both been charged with murder and attempted armed robbery. One is also charged with possession of a deadly weapon during the commission of a violent crime.

The news, which broke around noon Friday, sent shockwaves across UND and the Greater Grand Forks community. The incident became national news, with at least one national network reporting it during a 5:30 p.m. newscast.

DiLorenzo, 63, retired as provost of UND on June 1 after having been at the university for seven years.

His death comes six weeks after he retired from UND and a few weeks after he and his wife moved to Charleston.

Joshua Wynne, former interim president of UND and dean of the medical school, remembered DiLorenzo for his hard-working nature and commitment to UND.

To earn your retirement and then six weeks later be gone is incredibly sad, Wynne said. I'm sure he was working until the minute he walked out the door and locked it.

He cared deeply about UND, Debbie Storrs, interim provost at UND, said. "He encouraged us to think differently, look forward and envision a better university. He was committed to equity and hired many women into leadership positions.

Storrs said DiLorenzos new adventure was abruptly ended.

It is hard to put to words the sadness, especially in the world we live in today, she said. He will be missed. His impression on UND is felt, and we will continue to think forward.

Former UND Provost Tom DiLorenzo. (UND provided photo)

Gracie Lian, former student body president, said she was in a state of shock Friday after hearing the news.

He was always so warm and welcoming and ready to listen to the student voice, which I think was so important, Lian said, speaking of her time interacting with DiLorenzo. He really did care about student opinion on things.

Lian said she was especially impressed with DiLorenzos leadership during the COVID-19 pandemic as he was wrapping up his final months at UND. She said he was always reaching out to student leaders to ensure they were comfortable with the plans.

Tom worked tirelessly to help better UND, Matthew Ternus, UND student body president, told the Herald.

He said DiLorenzo was always a caring person who was ready to listen.

Tom was a servant leader during his time at UND, he said.

DiLorenzo served under presidents Robert Kelley and Mark Kennedy during his time at UND. He also served under interim presidents Ed Schafer and Wynne.

He arrived at UND in 2013 and worked to advance and lead initiatives to increase student retention and improve graduation rates. He was a central figure in the development of UND's strategic plan.

Former UND Provost Thomas DiLorenzo is pictured in this 2016 file photo. Jesse Trelstad/ Grand Forks Herald

When his retirement was announced in February he was lauded for his work with UNDs budget and knowledge of the university.

With his superhuman work ethic, Tom gave his heart and soul to the university up until his very last day at UND, said UND President Andrew Armacost, who assumed the president's role in June. He led the universitys response to the COVID-19 pandemic. He initiated programs that strengthened ties between UND and the Grand Forks community. And to improve the academic experience for UND students, he implemented programs that have resulted in better graduation and retention rates. Tom did all that was asked of him and then more. It was the kind of person he was.

During his time as interim president, Wynne effectively had three jobs: interim president, dean of the medical school and vice president of health affairs. Wynne said DiLorenzo made those jobs a little easier.

I think it's a true statement to say that I would not have been able to do all three of those jobs if it were not for the outstanding efforts of Provost DiLorenzo, Wynne said. He was incredibly hard working, of high integrity and tried to do the right thing.

North Dakota University System Chancellor Mark Hagerott said DiLorenzo was killed in an act of senseless violence. He said DiLorenzo was a key leader at UND.

He was a source of stability for UND, he said. He was also an intellectual leader in North Dakota as he pioneered new programs in robotics, cyber science and digital analytics.

Hagerott met DiLorenzo when Hagerott was serving at the U.S. Naval Academy Cyber Center, and said DiLorenzo was the first academic leader who encouraged him to return to North Dakota to serve in the university system.

Former UND President Mark Kennedy also expressed sadness Friday.

Tom cared, Kennedy said in a statement. He cared about his family. He cared about delivering on the mission of higher education to open up opportunities for students and the community.

DiLorenzo championed innovations that led to greater access to higher education for students, Kennedy said.

It was never about him, it was about the students, the faculty, the university, he said. The world is a better place because Tom lived.

Grand Forks Mayor Brandon Bochenski said the news of DiLorenzos death came as a great shock to our community. Bochenski said he and his wife, Jenny, are praying for DiLorenzos family and friends, as well as the many in Grand Forks that were fortunate to have known him.

Because of Dr. DiLorenzos dedication and the bonds he created, the path has been paved for a bright and prosperous future on campus and with UNDs partners, Bochenski said. Our community could not have been more blessed to have had such a strong advocate and leader.

Grand Forks City Administrator Todd Feland said he had the honor and privilege to work closely with DiLorenzo on a handful of strategic projects that are now hallmarks of the Grand Forks Town and Gown relationship.

Feland pointed to the internship program between the city and the university, research partnerships, the Coulee to Columbia infrastructure project and the Main Street GF Challenge as examples of those projects. Those projects would not have happened without DiLorenzos work ethic, greater-good attitude, and ability to work effectively with community stakeholders, Feland said.

He was a driving force in this community and this news hurts on a personal level, Feland said.

In a statement, College of Charleston President Andrew Hsu said DiLorenzo and his wife had moved to Charleston only a few weeks ago.

Tom was celebrated not only for his collaborative leadership style, but also his belief in experiential learning and how the city of Grand Forks served as an extension of the UND classroom, Hsu wrote. Given time, Tom would have seen parallels of that dynamic here in Charleston as well.

See original here:

UND campus in shock after recently retired Provost Tom DiLorenzo is killed in South Carolina robbery, arrests made - Grand Forks Herald

New data from MeiraGTx help bolster J&J’s gene therapy bet – BioPharma Dive

Dive Brief:

Thus far, Johnson & Johnson has not been a major player in gene therapy. Fellow large pharmas Roche, Novartis and Pfizer have each made more sizable bets, while biotechs like Bluebird bio, Sarepta and BioMarin have amassed pipelines of gene-based treatments, some of which are nearing regulatory approvals in the U.S.

Still, J&J has signaled some interest in gene therapy through partnerships, the most notable of which is its 2019 alliance with MeiraGTx. The $440 million pact gave J&J rights to a portfolio of treatments the biotech is developing for inherited retinal diseases.

The gene therapy reported on Friday at the annual meeting of the American Society of Retinal Specialists is one of those treatments and, given the results, likely the first that will be headed to late-stage testing.

Retinitis pigmentosa describes a group of diseases in which the light-sensing photoreceptor cells in the back of the eye deteriorate, leading to vision loss and potentially total blindness. The X-linked form, which mainly affects boys, is particularly severe and accounts for some 10% to 20% of cases. Visual deterioration typically begins in childhood, progressing to legal blindness at a median age of 45 years. A majority of those cases are caused by mutations to the RPGR gene.

No treatments are available to help stop the erosion of vision in XLRP patients. But the programs from Biogen acquired via its $800 million buyout of Nightstar Therapeutics and AGTC could change that, showing encouraging early results.

These therapies deliver a functional form of the RGPR gene into the eye, which then produces proteins meant to prevent photoreceptors from degenerating. So far, both of those gene therapies have shown an ability to increase retinal sensitivity in some, but not all patients.

Results published in Nature Medicine earlier this year, for instance, showed six of 18 patients injected with Biogen's gene therapy in an early-stage trial had improved ability in peripheral vision what's known as the visual field six months after treatment.

MeiraGTx and J&J, meanwhile, enrolled into their study 10 adults with XLRP caused by an RGPR mutation and delivered the gene therapy into one eye, with each patient's other eye serving as a control. The trial's goal was to show treatment is safe and to pick the best dose for further testing.

Five of the seven patients who received a low or medium dose had a meaningful improvement in multiple evaluations of retinal sensitivity six months after treatment. Signs of effectiveness were seen after three months, and either held up or improved with more follow-up.

In two of three patients given a high dose, however, the companies observed evidence of inflammation that they said contributed to "decreased activity" of the gene therapy. The inflammation, which wasn't seen at the lower doses, was managed with a course of steroids.

"The data look promising since they report improvement in retinal sensitivity across the visual field," Sherry Bass, a professor at SUNY College of Optometry in New York and a retinal disease researcher who isn't involved in the trial, wrote in an email to BioPharma Dive. XLRP patients lose their peripheral vision early in life, "so this is an exciting finding," she said.

Trial investigator Michel Michaelides, a professor of ophthalmology at University College London, said that the results show the gene therapy has "the potential to stabilize or slow progressive vision loss." More follow-up will be needed to bear that out, however.

The two companies aim to advance the treatment into a Phase 3 trial called Lumeos. Two other gene therapies from the pact, for forms of achromatopsia, or color blindness, are in Phase 1 testing.

MeiraGTx shares ticked up about 7% in early trading.

Read the rest here:

New data from MeiraGTx help bolster J&J's gene therapy bet - BioPharma Dive

WHO drafting paper on cell and gene therapies – Bioprocess Insider – BioProcess Insider

Regulators in high-income countries have a responsibility to help health authorities in low- and medium-income countries develop regulatory frameworks for cell and gene therapy products to ensure these treatments are available to all, asserts the US FDAs biologics centers director Peter Marks.

The World Health Organization plans to soon issue a white paper proposing a harmonized regulatory framework for cell and gene therapy products, according to Peter Marks, director of the US Food and Drug Administrations Center for Biologics Evaluation and Research. Such a framework is considered necessary for facilitating access to these products for patients in low- and medium-income countries and to ensure their commercial viability.

Marks discussed the WHOs plans and described some of the global regulatory challenges in bringing cell and gene therapies to market in at a 30 June webinar sponsored by the Parenteral Drug Association on advanced therapy medicinal products, where he also discussed some of the evolving regulatory requirements for these products in high-, middle- and lower-income countries.

Image: iStock/diegograndi

Marks, a proponent of using regulatory convergence to increase access to novel therapies, asserted that there is a responsibility for regulators in high-income countries to help regulators in low- and medium-countries develop the framework necessary so that some of these products are brought forward in their countries and are appropriate and are safe.

As he explained at a cell and gene therapy policy meeting in November, Marks expects that regulatory convergence among high-income countries could help facilitate commercial availability and pave the way for the use of gene therapies in low- and middle-income countries. He further suggested then thatlow- and middle-income countries adopt something akin to the WHOs prequalification process for vaccines.

In the high- and middle-income countries, the regulatory frameworks for cell and gene therapies are in a state of flux, Marks said. For cell therapies, there is a lack of alignment of regulations in high-income countries, while for gene therapies, there are more similarities.

At international meetings of regulators, the one thing that everyone can agree on is that the existing frameworks are not permanent and that some markets under-regulate while others over-regulate these products.

Yet in low- and middle-income countries, there is no framework at all. For these countries, it can be quite challenging for regulators to devise a framework from scratch. The issue that comes up is that with low- and middle-income countries, they have no experience with cell and gene therapies. If you have to develop regulations out of nothing, it can be quite challenging. When you think about it, small countries have a regulatory agency that consists of a few dozen people.

Rather than having these health authorities devise regulations from scratch, it would be better to leverage a harmonized regulatory framework that has already been developed by other higher-income countries that have more experience in novel therapies.

Marks is on the WHO team that is developing the white paper, or unified regulatory schema, for regulatory convergence on cell and gene therapies.

He said he hopes the white paper will bring some order to this area. The team was making a lot of progress on this before COVID-19 came along, and he expects that the WHO will be publishing this paper in the not too distant future.

Marks said that some possible areas of regulatory convergence could include preclinical study requirements for toxicology studies, environment assessments, manufacturing information, clinical outcomes and inspectional requirements.

The idea for the white paper emerged from a September 2018 meeting of the International Conference of Drug Regulatory Authorities (ICDRA) in Dublin, Ireland.

ICDRAs press release from the meeting said that the WHO would develop with member states a current state of the art document capturing areas where agreement among experienced regulatory authorities exists, noting where harmonization has yet to be achieved, and documenting existing areas of uncertainty; areas covered could include definitions, quality attributes, standards and clinical development pathways.

ICDRA was established in 1980 to bring together regulatory authorities from WHO member states to strengthen collaboration and develop international consensus on regulatory priorities.

Marks said that global regulatory convergence for these products will help ensure that the markets for cell and gene therapies are large enough for commercial viability.

Many gene therapies for ultra-rare diseases target small patient populations enrolling up to 100 patients a year. One country may not have enough patients with a rare disorder to make it commercially viable for a company to launch the product. However, Marks said, if you market across countries you can get to that commercial viability.

Marks emphasized, as he had at the November cell and gene therapy policy meeting, that sponsors should ask officials with other authorities such as the European Medicines Agency to join some some of their meetings with the US FDA as a way to come together to develop enough national markets for the scale required to make many cell and gene therapies viable.

At the PDA webinar, Marks encouraged sponsors to promote convergence by inviting other regulators to attend their pre-IND Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) meetings with the FDA. This could go a long way toward educating other authorities on how the FDA assesses potential cell and gene therapy products.

CBER announced in June 2018 the implementation of the INTERACT program, which is intended to help accelerate development and approval of novel biologics and other products reviewed by the center.

We are perfectly happy if a sponsor invites other regulators to listen in on early meetings, said Marks. We have no problem with regulators from other countries listening in on these meetings because it could orient them to some very interesting products that they otherwise would not have exposure to.

Read the original post:

WHO drafting paper on cell and gene therapies - Bioprocess Insider - BioProcess Insider

Gene Therapy Market Size Is Expected to Grow at a CAGR of 40.7% By 2025 | Share Analysis, Growth Outlook, COVID-19 Impact and Size Estimation -…

(MENAFN - iCrowdNewsWire) Jul 17, 2020

Gene Therapy Market Research Report: By Product (Kymriah, Luxturna, Yescarta, Zolgensma, Strimvelis, Zynteglo, Others), By Indication (Oncology, Genetic Diseases, Others) and By End-User (Hospitals & Clinics, Specialty Treatment Centers), Forecast to 2025

Gene Therapy Market Landscape

The Gene Therapy Market size in 2018 was valued at USD 524 million. It is likely to grow at a whopping 40.7% CAGR by 2025, as per the Market Research Future's (MRFR) new report. Gene therapy comprises replacing, repressing, and repairing dysfunctional genes that cause disease. The aim of this promising treatment is in re-establishing the normal function. This therapy helps to treat different genetic diseases such as inherited disorders, namely cancer & viral infections, and some specific genetic diseases, namely muscular dystrophy & cystic fibrosis.

Numerous factors are propelling the global gene therapy market growth. These factors, as per the new MRFR report, comprise increasing funds for gene therapy research, availability of favourable reimbursements, increasing cases of cancer & other target diseases, and strategic collaborations & product launches made by key players for staying ahead in the competition. Besides, rising cases of target diseases, large investments made by top market players, and robust product pipeline are also adding gene therapy market growth.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/8399

On the contrary, strict regulatory policies coupled with high product development cost are factors that may deter the gene therapy market growth over the forecast period as per the gene therapy market forecast.

Gene Therapy Market Segmentation

The global gene therapy market has been segmented based on indication, product, and end user.

By product, the gene therapy market is segmented into yescarta, zynteglo, luxturna, imlygic, kymriah, zolgensma, strimvelis, and others.

By indication, the gene therapy market is segmented into oncology, genetic disorders/diseases, and others. Among these, the oncology segment will have a major share in the market over the forecast period. The robust cancer gene therapy pipeline, coupled with surging cancer cases, is adding to the growth of the segment.

By end user, the gene therapy market is segmented into hospitals and clinics, the specialty treatment centre, & others. Among these, hospitals & clinics will lead the market over the forecast period. The burgeoning number of hospitals, coupled with hospitals & clinics being the foremost choice to treat diseases, is boosting the growth of this segment.

Gene Therapy Market Regional Analysis

Based on the region, the global gene therapy market report covers the recent trends and growth opportunities across Europe, North America, the Asia Pacific (APAC), and the Middle East and Africa (MEA). Of these, North America will have lions share in the market over the forecast period for the rising cases of chronic diseases, increasing healthcare expenditure, advanced & innovative healthcare infrastructure, presence of eminent market players, and availability of favorable reimbursements.

The global gene therapy market in Europe is predicted to have favorable growth over the forecast period for industry players coming up with innovative product launches, top companies in the region extending product distribution by securing approval from various regulatory bodies, and increasing expenditure for gene and cell therapy companies in the UK.

The global gene therapy in the Asia Pacific region is likely to grow at a fast pace during the forecast period. The rising government initiatives for the healthcare sector development, presence of top market players in the region, launch & approval of various gene therapy products, rising prevalence of chronic diseases, and growing awareness about gene therapy are adding market growth.

The global gene therapy market in the Middle East and Africa is predicted to hold the smallest share over the forecast period for restricted healthcare infrastructure in the region.

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/gene-therapy-market-839

Gene Therapy Market Key Players

Eminent players in the global gene therapy market include Orchard Therapeutics plc (UK), Novartis AG (Switzerland), Lonza (Switzerland), CEVEC (Germany), Amgen, Inc. (US), Gilead Sciences, Inc. (US), Thermo Fisher Scientific Inc. (US), Spark Therapeutics, Inc. (US), Bristol-Myers Squibb Company (US), Celgene Corporation (US),and uniQure N.V (Netherlands).

Table Of Contents

Chapter 1. Report Prologue

Chapter 2. Gene Therapy Market Introduction

Definition

Scope Of The Study

Research Objective

Assumptions

Limitations

Chapter 3. Research Methodology

Introduction

Primary Research

Secondary Research

Market Size Estimation

Chapter 4. Gene Therapy Market Dynamics

Drivers

Restrains

Opportunities

Challenges

TOC Continued

Browse More Healthcare Research Reports at:

Intraoperative Neurophysiological Monitoring Market Trends, Size and Application, By Type (EEG, EMG and Evoked Potential (EP)), Method (Invasive, Non-Invasive and Minimally Invasive), Source (In-house, Outsource and Tele-Health), Procedure (Spinal, Neurovascular, Orthopedic, Otolaryngology Surgery, Urology and others) and Region (North America, Europe, Asia-Pacific and the Middle East & Africa) - Forecast to 2027https://www.marketresearchfuture.com/reports/intraoperative-neurophysiological-monitoring-market-729

Healthcare IoT Security Market Research Report: Information by Component (Solution and Services), Solutions Type (Analytics, Encryption, Data Loss Protection, Identity and Access Management and Unified Threat Management), Service Type (Consulting Services, Risk Assessment Services, Design & Integration Services and Managed Security Services), Security Type (Application, Cloud, Endpoint and Network), Application (Pharmaceutical, Medical Devices and Biotechnology) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2025https://www.marketresearchfuture.com/reports/healthcare-iot-security-market-946

Ultra-low Temperature Freezers Market: Information by Type (Upright, Chest), Degree of Cooling (-41C to -86 C Freezers, -87C to -150 C Freezers), Application (Blood & Blood Products, Biological Samples, Drug Compounds, Others), End-User (Bio-Banks, Hospitals & Clinics, Academic & Research Laboratories, Others) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2027https://www.marketresearchfuture.com/reports/ultra-low-temperature-freezer-market-1813

NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

See the rest here:

Gene Therapy Market Size Is Expected to Grow at a CAGR of 40.7% By 2025 | Share Analysis, Growth Outlook, COVID-19 Impact and Size Estimation -...

The Global Viral Vector & Plasmid DNA Manufacturing Market is Expected to Reach US$ US$ 2247.7 Million by 2027 From US$ 459.4 Million in 2019 -…

NEW YORK, July 16, 2020 /PRNewswire/ --

Read the full report: https://www.reportlinker.com/p05932695/?utm_source=PRN

Driving factors such as growing awareness of gene therapy, increasing prevalence of genetic disorders and infectious diseases across the world are expected to upsurge the market growth.Additionally, growth in the global healthcare market is likely to have a positive impact on the market in coming years.

However the high cost associated with gene therapy is the major factor hindering the market growth.

Gene therapies offer an effective way for the treatment of genetic diseases, the acceptance and awareness of gene therapy continues to grow, especially in developed regions.The increase in awareness of gene therapies leads to market entry of new and established players for manufacturing various gene therapy technologies.

For instance, according to a study published by Alliance for Regenerative Medicine in 2018, the number of gene therapy-related clinical trials witnessed growth of an estimated 18.0% compared to the previous year across the world. This growth in the number of clinical trials indicates rise in awareness and massive investments.

Established companies, healthcare organizations, and research institutes are focusing on spreading awareness related to gene therapies as they offer a modern way of disease treatment.For instance, in 2018, Alliance for Regenerative Medicine announced the launch of a new foundation to promote comprehensive understanding and acceptance of gene therapies.

This newly formed organization will work to grow public awareness and benefits of certain gene therapy-based aspects such as cell therapy, tissue-engineering, gene editing, and organ regeneration.

The global viral vector & plasmid DNA manufacturing market is segmented by product and application.Based on product, the viral vector & plasmid DNA manufacturing marketis segmented into viral vectors and non-viral vectors.

The viral vectors segment held the larger share of the market in 2019 andis anticipated to register the higher CAGR during the forecast period.Based on application, the viral vector & plasmid DNA manufacturing markethas been segmented into cancer, inherited disorders, viral infections, and others.

The cancersegment held the largest share of the market in 2019 and the same segment is estimated to register the highest CAGR in the market during the forecast period.

National Institutes of Health, World Health Organization (WHO), European Medical Association, Centers for Disease Control and Prevention, Canada Foundation of Innovation, Contract Research Organizations, and Dubai Health Authority are some of the essential secondary sources included in the report.

Read the full report: https://www.reportlinker.com/p05932695/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Contact Clare: [emailprotected] US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

http://www.reportlinker.com

Continue reading here:

The Global Viral Vector & Plasmid DNA Manufacturing Market is Expected to Reach US$ US$ 2247.7 Million by 2027 From US$ 459.4 Million in 2019 -...

Covid-19 Recovery: Outlook on the Worldwide Gene Therapy Industry to 2025 – Cole of Duty

Global Gene Therapy Market Research Report 2020: COVID-19 Outbreak Impact Analysis

Brand Essence Market Research has developed a concise study on the Gene Therapy market to depict valuable insights related to significant market trends driving the industry. The report features analysis based on key opportunities and challenges confronted by market leaders while highlighting their competitive setting and corporate strategies for the estimated timeline.

Download Sample PDF (including full TOC, Tables, and Figures) of Gene Therapy Market Research 2020-2026:- https://brandessenceresearch.biz/Request/Sample?ResearchPostId=72699&RequestType=Sample

Global Gene therapy market is valued at USD 0.67 Billion in 2018 and expected to reach USD 5.18 Billion by 2025 with the CAGR of 33.9 % over the forecast period. Increasing prevalence of the cardiovascular disease, cancer, genetic disorder, and painful existing treatment procedure is further driving Gene therapy market.

Gene Therapy is associated with the experimental technique that uses genes to treat or prevent disease. In the future, this system could permit doctors to treat a condition by inserting a gene into patients cells rather than exploitation medication or surgery. Gene therapy replaces a faulty gene or adds a new gene in an attempt to cure disease or improve bodys ability to fight disease. Gene therapy holds potential for treating a wide range of diseases, such as cancer, cystic fibrosis, heart disease, diabetes, hemophilia and AIDS. For example, suppose a brain tumor is forming by rapidly isolating cancer cells.

Global gene therapy market report is segmented on the basis of Therapy type, Vector Type, application, and regional& country level. Based upon Therapy type, gene therapy market is classified as somatic and germline. Based upon Vector type Gene Therapy Market is classified into non-viral vectors and viral vectors. Based upon Application Gene therapy market is classified into Cancer Diseases, Monogenic Diseases, Infectious Diseases, Cardiovascular Diseases, Others.

The regions covered in this Global Gene therapy market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of Gene therapy is sub divided into U.S., Mexico, Canada, UK, France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Key Players for Global Gene therapy Market ReportsGlobal Gene therapy market Report covers prominent players are like Sangamo, Spark Therapeutics, Dimension Therapeutics, Avalanche Bio, Celladon, Vical, Advantagene.

Increasing prevalence of cardiovascular disease, cancer, genetic disorder, and painful existing treatment procedure is expected to grow Gene therapy market. Growing prevalence of cardiovascular disease, cancer, genetic disorder, and painful existing treatment procedure coupled with the increasing application of public health and clinical facilities is expected to drive Gene therapy market. As this therapy is transforming the current approaches to promote the excellence in health and prevent from cardiovascular diseases such as cancer and diabetes. In 2017, it is projected that around 14% (more than 34 million adults) were current smokers. While People with diabetes comprise 8.8% of the worlds population and IDF predicted that the number of cases of diabetes will rise to 642 million by 2040. In low-income countries, mainly in Africa, the older population faces a considerable burden of both non-communicable and communicable diseases. High cost of gene therapy treatment and unwanted immune responses such factors hindering the growth of gene therapy market. Technological Advancements leading to provide better technological procedures is the lucrative opportunity for gene therapy market in forecast period.

Geographically, this report split global into several key Regions, revenue (Million USD) The geography (North America, Europe, Asia-Pacific, Latin America and Middle East & Africa) focusing on key countries in each region. It also covers market drivers, restraints, opportunities, challenges, and key issues in Global Gene Therapy Market.

Key Benefits for Gene Therapy Market Reports Global market report covers in-depth historical and forecast analysis. Global market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level. Global market report helps to identify opportunities in market place. Global market report covers extensive analysis of emerging trends and competitive landscape.

By Disease Indication Cancer Genetic disorders Cardiovascular diseases Ophthalmology Neurological conditions Others

By Type of Vectors Viral vectors Non-viral vectors

By Type of Cells Somatic cells Germline cells

By Region North Americao U.S.o Canadao Mexico Europeo UKo Franceo Germanyo Russiao Rest of Europe Asia-Pacifico Chinao South Koreao Indiao Japano Rest of Asia-Pacific LAMEAo Latin Americao Middle Easto Africa

North America is dominating the Gene therapy Market North America is dominating the gene therapy market during the forecast period due to increasing healthcare expenditure coupled with advancement of technologies. The majority of gene therapies clinical trials recognized targeted cancer diseases. In the US, around 66.81% of gene therapy clinical trials are carried out. While all other countries participated in a small percentage of the trials such as 9.45% in the UK, 3.95% in Germany and around 2% each in Switzerland, France, China, and Japan. Globally, regeneration medicine companies providing Gene cell therapy and tissue engineering for therapeutic developers is expected to grow gene therapy market in this region.

Gene Therapy Market Key Players: Pfizer Inc. Novartis AG Bayer AG Sanofi GlaxoSmithKline plc. Amgen Inc. Boehringer Ingelheim International GmbH uniQure N.V. bluebird bio, Inc. Celgene Corporation Others

This comprehensive report will provide:

Enhance your strategic decision making Assist with your research, presentations and business plans Show which emerging market opportunities to focus on Increase your industry knowledge Keep you up-to-date with crucial market developments Allow you to develop informed growth strategies Build your technical insight Illustrate trends to exploit Strengthen your analysis of competitors Provide risk analysis, helping you avoid the pitfalls other companies could make Ultimately, help you to maximize profitability for your company.

Our Market Research Solution Provides You Answer to Below Mentioned Question:

Which are the driving factors responsible for the growth of market? Which are the roadblock factors of this market? What are the new opportunities, by which market will grow in coming years? What are the trends of this market? Which are main factors responsible for new product launch? How big is the global & regional market in terms of revenue, sales and production? How far will the market grow in forecast period in terms of revenue, sales and production? Which region is dominating the global market and what are the market shares of each region in the overall market in 2017? How will each segment grow over the forecast period and how much revenue will these segment account for in 2025? Which region has more opportunities?

>>>>Get Full Customize report@ https://brandessenceresearch.biz/Request/Sample?ResearchPostId=72699&RequestType=Customization

Our industry professionals are working reluctantly to understand, assemble and timely deliver assessment on impact of COVID-19 disaster on many corporations and their clients to help them in taking excellent business decisions. We acknowledge everyone who is doing their part in this financial and healthcare crisis.

The Essential Content Covered in the GlobalGene Therapy Market Report:

* Top Key Company Profiles.* Main Business and Rival Information* SWOT Analysis and PESTEL Analysis* Production, Sales, Revenue, Price and Gross Margin* Market Share and Size

The report provides a 6-year forecast (2020-2026) assessed based on how the Gene Therapy market is predicted to grow in major regions like USA, Europe, Japan, China, India, Southeast Asia, South America, South Africa, Others.

Strategic Points Covered in TOC:

Chapter 1:Introduction, market driving force product scope, market risk, market overview, and market opportunities of the global Gene Therapy market.

Chapter 2:Evaluating the leading manufacturers of the global Gene Therapy market which consists of its revenue, sales, and price of the products.

Chapter 3: the competitive nature among key manufacturers, with market share, revenue, and sales.

Chapter 4:Presenting global Gene Therapy market by regions, market share and revenue and sales for the projected period.

Chapters 5, 6, 7, 8 and 9:To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions.

Read More: https://brandessenceresearch.biz/Lifesciences-and-Healthcare/Gene-Therapy-Market-Share/Summary

About us: Brandessence Market Research and Consulting Pvt. ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact us at: +44-2038074155 or mail us at[emailprotected]

Top Trending Reports:

https://technologyindustrynews.com/railway-management-system-market-2020-by-advanced-technologies-growth-opportunities-key-players

https://technologyindustrynews.com/restaurant-management-software-market-share-size-analysis-with-industry-segment-2020-manufacturers

https://industrywatchnews.com/porcine-vaccines-market-scenario-strategies-growth-factors-opportunities-analysis-and-forecast-by

https://industrywatchnews.com/cell-banking-outsourcing-market-size-overview-by-industry-trends-share-growth-factor

https://industrywatchnews.com/artificial-embryo-market-overview-by-share-size-market-players-revenue-and-product

Continued here:

Covid-19 Recovery: Outlook on the Worldwide Gene Therapy Industry to 2025 - Cole of Duty

2020 to 2027 Global Gene Therapy Market Report 2020 COVID 19 Impact Analysis Updated Edition Top Players Include, Kite Pharma, BioVex, Novartis, Spark…

Global Coronavirus pandemic has impacted all industries across the globe, Gene Therapy market being no exception. As Global economy heads towards major recession post 2009 crisis, Cognitive Market Research has published a recent study which meticulously studies impact of this crisis on Global Gene Therapy market and suggests possible measures to curtail them. This press release is a snapshot of research study and further information can be gathered by accessing complete report.

Checkout Inquiry for Buying or Customization of Report: https://www.cognitivemarketresearch.com/manufacturingconstruction/gene-therapy-market-report#download_report.

The number of coronavirus cases is increasing rapidly which has not only taken a number of lives but has also affected the global economic structure. The Coronavirus Disease Pandemic (COVID-19) has affected all parts of the world. This virus has changed all the market conditions and hampers the growth of the various sectors of the global Gene Therapy market. The report covers rapidly altering market scenario due to COVID-19 and market fluctuation during the forecast period. Cognitive Market Research has published Gene Therapy market report accordingly.To Get Detailed Analysis Mail us @ [emailprotected] or call us on +1-312-376-8303.

The global Gene Therapy market report covers in-depth impression of regional level break-up, leading growth rate territory, countries with the highest market share, geographical break-up, market size, status, upcoming technologies, industry drivers, challenges, regulatory policies, with key company profiles and strategies of players. The report also offers comprehensive evaluation of the market, current growth factors, focused opinions and industry certified market data.

Request Free Sample Copy @ https://www.cognitivemarketresearch.com/manufacturingconstruction/gene-therapy-market-report#download_report

The global Gene Therapy Market can be segmented into various type and application. All the type and application segments have been analyzed based on present and future trends and the market is estimated from 2020 to 2027. Moreover, study also provides quantitative and qualitative analysis of each type to understand the driving factors for the fastest growing type segment for Gene Therapy market.

Global Gene Therapy Market Segmentation: By Types Ex Vivo, In Vivo

Global Gene Therapy Market segmentation: By Applications Cancer Diseases, Hematological Disease, Hereditary Disease

Manufacturers are facing continued downward pressure on demand, production and revenues as the COVID-19 pandemic strengthens.manufacturers should be prepared for major global supply chain disruptions. Thus, some of the key players are mainly focusing on research & development to provide inovative products to clint.Major Key Players mentioned in the report are: Kite Pharma, BioVex, Novartis, Spark Therapeutics

Global Gene Therapy Market Segmentation: By RegionGlobal Gene Therapy market report categorized the information and data according to the major geographical regions like, North America (U.S., Canada, Mexico)Europe (U.K., France, Germany, Spain, Italy, Central & Eastern Europe, CIS)Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific)Latin America (Brazil, Rest of L.A.)Middle East and Africa (Turkey, GCC, Rest of Middle East)

The Global Gene Therapy Market report covers all dynamic limitations along with Gene Therapy market upsurges, market trends and opportunities, feasibility evaluation, market drivers and restrains, market competitive landscape and guidelines on new investments. The report also covers all the data by market applications, by product types, by geographic regions and information about the suppliers and the investors.

Enquire Here For Discount (COVID-19 Impact Analysis Updated Sample): Click Here>Download Sample Report of Gene Therapy Market Report 2020 (Coronavirus Impact Analysis on Gene Therapy Market)

There are 15 Chapters to display the Global Gene Therapy market:Chapter 1: Market Overview, Drivers, Restraints and Opportunities, Segmentation

OverviewChapter 2: COVID ImpactChapter 3: Market Competition by ManufacturersChapter 4: Production by RegionsChapter 5: Consumption by RegionsChapter 6: Production, By Types, Revenue and Market share by TypesChapter 7: Consumption, By Applications, Market share (%) and Growth Rate byApplicationsChapter 8: PESTEL AnalysisChapter 9: Complete profiling and analysis of ManufacturersChapter 10: Manufacturing cost analysis, Raw materials analysis, Region-wiseManufacturing expenses.Chapter 11: Industrial Chain, Sourcing Strategy and Downstream BuyersChapter 12: Marketing Strategy Analysis, Distributors/TradersChapter 13: Market Effect Factors AnalysisChapter 14: Market ForecastChapter 15: Gene Therapy Research Findings and Conclusion, Appendix, methodology and data source.To access the complete Table of Content click here: @ https://www.cognitivemarketresearch.com/manufacturingconstruction/gene-therapy-market-report#table_of_contents

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

About Us: Cognitive Market Research is one of the finest and most efficient Market Research and Consulting firm. The company strives to provide research studies which include syndicate research, customized research, round the clock assistance service, monthly subscription services, and consulting services to our clients. We focus on making sure that based on our reports, our clients are enabled to make most vital business decisions in easiest and yet effective way. Hence, we are committed to delivering them outcomes from market intelligence studies which are based on relevant and fact-based research across the global market.Contact Us: +1-312-376-8303Email: [emailprotected]Web: https://www.cognitivemarketresearch.com/

Read the original post:

2020 to 2027 Global Gene Therapy Market Report 2020 COVID 19 Impact Analysis Updated Edition Top Players Include, Kite Pharma, BioVex, Novartis, Spark...

Novartis Launches Initiative to Supply COVID-19 Therapies to Low and Middle-Income Countries – BioSpace

Switzerlands Novartis launched an initiative to assist patients in low-income and lower-middle-income countries in getting access to affordable drugs for COVID-19. Specifically, they are making 15 drugs from its Sandoz division available that can be used to treat symptoms related to COVID-19. They are drugs for gastrointestinal illness, acute respiratory symptoms, pneumonia and septic shock.

Novartis plans to make the drugs available to government, non-governmental organizations (NGOs) and other institutional customers in up to 79 countries at no profit. In addition, the initiative will allow the countries to pick therapies in the portfolio that they need. The primary eligibility requirement is that the countries are on the World Banks list of low-income and lower-middle-income (LIC; LMIC) countries.

Access to medicine can be a challenge for patients in low- and lower-middle-income countries and the situation has worsened during COVID-19, said Lutz Hegemann, chief operating officer for Global Health at Novartis. With our COVID-19 portfolio, we wish to help address the additional healthcare demands of the pandemic in the countries we are targeting.

The drugs included in the Novartis COVID-19 Response Portfolio are: Amoxicillin, Ceftriaxone, Clarithromycin, Colchicine, Dexamethasone, Dobutamine, Fluconazole, Heparin, Levofloxacin, Loperamide, Pantoprazole, Prednisone, Prednisolone, Salbutamol and Vancomycin.

The company indicates the portfolio is in addition to the Novartis Access portfolio, which are on- and off-patent medicines against key non-communicable diseases, by way of the local Novartis or Sandoz affiliate.

According to Reuters, Novartis initiative caused the NGO Doctors Without Borders to call for more drug pricing transparency and for the biopharmaceutical industry to follow no profiteering initiatives for new COVID-19 therapies.

Hegemann told Reuters that the company has not had supply chain problems for these drugs, but the focus was on ensuring that the vulnerable healthcare systems in Africa, Asia, South America and Eastern Europe didnt become overwhelmed.

We shouldnt underestimate the stress that COVID puts particularly on fragile health system, Hegemann told Reuters. He said the company planned to work with health authorities, faith-based organizations and NGOs to eliminate markups on drugs. We are not targeting classical commercial distribution channels, but very direct channels.

For the most part, Novartiss branded drugs arent commonly used to treat COVID-19, and its malaria drug hydroxychloroquine has had very mixed results in clinical trials for the disease. But Sandoz is the Swiss companys generics division and has many drugs that are used to treat symptoms of COVID-19 in patients in the hospital. They are typically steroids, antibiotics, an antifungal and lung medication. Most of them have been around for decades and are relatively inexpensive to manufacture.

Novartis should publish the actual at cost prices for these medicines, as well as any costs of R&D and costs of production for all of their medicines, a spokesperson for Doctors Without Borders said. Additionally, we hope that corporations like Novartis will follow similar no profiteering initiatives for any new COVID-19 products.

To date, Novartis has donated $40 million in support of communities globally impacted by the pandemic. They are also involved in two cross-industry research programs, the COVID-19 Therapeutics Accelerator, coordinated by the Bill & Melinda Gates Foundation, Wellcome Trust, and Mastercard, and a COVID-19 directed partnership organized by the Innovative Medicines Initiative (IMI).

It is still supplying hydroxychloroquine for investigator-initiated clinical trials and when governments require it, as appropriate. It is also supporting clinical trials of several of its drugs for COVID-19. In addition, AveXis, its gene therapy unit, inked a manufacturing agreement with Massachusetts Eye and Ear and Massachusetts General Hospital to manufacture its novel genetic COVID-19 vaccine candidate, AAVCOVID.

This initiative builds on our earlier global commitment to keep prices stable for a basket of essential drugs used to treating COVID-19 patients, said Richard Saynor, chief executive officer of Sandoz. The COVID-19 Response Portfolio for low-income and lower-middle-income countries is designed to support governments in treating COVID-19 symptoms before they lead to complications in patients.

See the original post here:

Novartis Launches Initiative to Supply COVID-19 Therapies to Low and Middle-Income Countries - BioSpace

A Jennifer Doudna-led team finds a new CRISPR enzyme in the giant viruses of a California mud bog – Endpoints News

A day after Moderna and the NIH published much-anticipated data from their Phase I Covid-19 vaccine trial, attention is turning to AstraZeneca which, according to a UK report, is expected to publish its own early data tomorrow.

ITVs Robert Peston reported that AstraZeneca will publish the Phase I data inThe Lancet.

AstraZeneca and Moderna represent the two most ambitious Covid-19 vaccine efforts, having set the quickest timelines for approval (though they were recently joined in that regard by the Pfizer-BioNTech partnership) and some of the loftiest goals in total doses. Yet there is even less known about AstraZenecas vaccines effect on humans than there was about Modernas before yesterday. Although, in a controversial move, Moderna released some statistics from its Phase I in May, AstraZeneca has yet to say anything about what it saw in its Phase I trial a move consistent with the scientific convention to withhold data until it can be published in a peer-reviewed journal.

Read More

Originally posted here:

A Jennifer Doudna-led team finds a new CRISPR enzyme in the giant viruses of a California mud bog - Endpoints News

Biotech Firms to Track and Monitor Patients Injected with Stem Cells or Gene Therapy Treatments – The Korea Bizwire

The new business entities should stop the supply and sale of human cells once they are verified to be harmful to human bodies. (Yonhap)

SEOUL, July 16 (Korea Bizwire) New government regulations will require South Korean biotech companies to track and monitor patients who are injected with stem cells or gene therapy treatments.

According to the Ministry of Food and Drug Safety on Wednesday, the Advanced Regenerative Bio Act, enacted to strengthen the safety management of advanced regenerative drugs as well as to facilitate their commercialization through rapid clinical studies, will take effect on Aug. 28.

Under this law, a new type of business called human cell management will be born, which will clear the way for professional management of human and animal cells and tissues in addition to animal organs.

During the process of operation, the new business entities should stop the supply and sale of human cells once they are verified to be harmful to human bodies.

In such cases, all of the human cells concerned should be withdrawn and disposed of.

The law will make it mandatory for biotech companies to register stem cell and gene therapy treatment injection data with the Korea Institute of Drug Safety & Risk Management.

They will also be obliged to report unusual cases and perform long-term tracking and monitoring of the patients.

Advanced regenerative medicine refers to the medical technology of curing, replacing or regenerating damaged cells or issues using human cells.

Kevin Lee (kevinlee@koreabizwire.com)

Excerpt from:

Biotech Firms to Track and Monitor Patients Injected with Stem Cells or Gene Therapy Treatments - The Korea Bizwire

Eli Lilly’s mirikizumab joins the club beating up on Cosentyx as another head-to-head study leaves Novartis’ drug in the dust – Endpoints News

A day after Moderna and the NIH published much-anticipated data from their Phase I Covid-19 vaccine trial, attention is turning to AstraZeneca which, according to a UK report, is expected to publish its own early data tomorrow.

ITVs Robert Peston reported that AstraZeneca will publish the Phase I data inThe Lancet.

AstraZeneca and Moderna represent the two most ambitious Covid-19 vaccine efforts, having set the quickest timelines for approval (though they were recently joined in that regard by the Pfizer-BioNTech partnership) and some of the loftiest goals in total doses. Yet there is even less known about AstraZenecas vaccines effect on humans than there was about Modernas before yesterday. Although, in a controversial move, Moderna released some statistics from its Phase I in May, AstraZeneca has yet to say anything about what it saw in its Phase I trial a move consistent with the scientific convention to withhold data until it can be published in a peer-reviewed journal.

Read More

More:

Eli Lilly's mirikizumab joins the club beating up on Cosentyx as another head-to-head study leaves Novartis' drug in the dust - Endpoints News

Need to Get Away? Heres Every Space Tourism Vacation You Can Book Right Now – Observer

Things arent going so great on the planet Earth right now, and travel isnt easy, but if youve got a bit of cash, you can really get away. A number of well-capitalized companies have been hacking away at Space Tourism, or commercially flying regular people into space, and now its on the verge of reality. Thanks to a great deal of financial and human capital put in by organizations ranging from NASA to billionaire-backed startups, we are inches close to turning it into reality.

Space vacation packages come in a wide variety. For beginners, British billionaire Richard Bransons Virgin Galactic is offering a 1.5-hour joy ride to the edge of the Earths atmosphere. NASA is opening the International Space Station to private citizens. And, for hard-core space explorers, Elon Musks SpaceX has promised to fly you to the Moon (for a hefty price) in as soon as 2023.

Below weve put together the latest statuses of various space tourism projects in the market.

Destination: Edge of the Earths atmosphere

Price: $250,000 per person

Earliest available time: late 2020

Virgin Galactics supersonic spaceplane, VSS Unity, will fly passengers up to 100 kilometers (62 miles) above sea level, which is right above the Krmn Line dividing the Earths atmosphere and outer space. From there, passengers will get a stunning view of the Earths curvature. Then, during the descent, they will experience several minutes of weightlessness like a true astronaut.

VSS Unity has completed two successful human test flights and is in its final stage of testing. Virgin Galactic plans to fly its first paying customer, possibly the companys founder Richard Branson himself, as soon as this year.

Destination: The edge of the Earths atmosphere

Price: $200,000 and $300,000

Earliest available time: unknown

Blue Origin, owned by Amazon CEO Jeff Bezos, is developing a suborbital tourism program similar to Virgin Galactics but using a vertical-takeoff, vertical-landing (VTVL) rocket-capsule system called New Shepard. The New Shepard spacecraft has successfully flown above the Krmn Line and returned to the ground.

Blue Origin had planned to launch its first human test flight in 2019 and begin selling commercial tickets (reportedly priced between $200,000 and $300,000) soon after. Yet, the plan was quietly canceled last year. The company has yet to make public statements about new test and rollout dates.

Destination: International Space Station

Price: $35,000 per night

Earliest available time: late 2020

In June 2019, NASA unveiled its grand plan to allow private citizens to fly to the International Space Station under the agencys Commercial Crew Program. Passengers will fly in either SpaceXs Crew Dragon spacecraft or Boeings Starlinervessel.

The Crew Dragon recently completed its final crewed test and is ready to be deployed for commercial missions. NASA has said it will allow up to two private trips to the ISS a year, each lasting up to 30 days. The total cost of the trip would be around $50 million per person, the agency said.

Destination: the Moon

Price: Not a trivial amount

Earliest available time: 2023

Elon Musks rocket company SpaceX has the ultimate space vacation offering: a personalized trip to the Moon. The package has one committing customer so far: Japanese fashion mogul Yusaku Maezawa, who signed up for the trip in September 2018 and has put down an undisclosed deposit. Musk has said the full ticket price is not a trivial amount.

SpaceX is currently building prototypes for the rocket (Big Falcon Rocket (BFR) rocket) and spaceship (Starship) that will fly Maezawa to the Moon. If all tests go according to the plan, a human launch could take place as early as 2023.

Link:

Need to Get Away? Heres Every Space Tourism Vacation You Can Book Right Now - Observer

‘They’re really good men’: Victoria Beckham is proud of her sons – Opelika Auburn News

Victoria Beckham feels "really proud" of her sons.

The 46-year-old designer has Brooklyn, 21, Romeo, 17, and Cruz, 15, with her husband David Beckham - with whom she also has nine-year-old daughter Harper - and has said she couldn't be happier with the way her sons are growing up, as they're "turning out to be really good men".

She said: "I feel really proud of our boys because they are turning out to be really good men. They work hard and they're kind, and being kind is key now. I think everybody should be kind - there are so many horrible things going on in the world. With regards to the boys they always have to have respect for themselves, for others, for girls. Our boys have always had the utmost respect for everyone. They have always been like that."

And for the former Spice Girls star, motherhood is her greatest achievement.

She added during an interview with photographer Alexi Lubimorski for his YouTube series: "Being a mum is the most important job in the world. I love what I do professionally and I take it very seriously but there is nothing more serious than having children. It's your responsibility to bring up really good, good people so I take that responsibility seriously. I try to be the best mum, I try to be the best wife, and I try and be the best professional."

Victoria has been staying at home with her family amid the coronavirus pandemic, and recently said her time in lockdown has been "precious".

She explained: "While working from home, we've been on walks every day as a family. How often would we all go on a walk together normally? Usually there's a conference call or a work meeting or someone is travelling abroad. These times are precious.

View post:

'They're really good men': Victoria Beckham is proud of her sons - Opelika Auburn News

Commentary: Conservatives will defeat themselves if they don’t wake up to social media reform – The Daily World

By Rudolph Bush

The Dallas Morning News

In a move that interested few and mattered less, Texas state Rep. Jonathan Stickland announced to Twitter on July 2 that enough was enough. He was leaving the platform for a place where he felt he could express himself full bore without the liberal idiots with mob mentality that have taken over here.

The Bedford, Texas, Republican promised to check his account infrequently, a pledge that turned out to be too good to be true since his Twitter thumb has remained pretty active in the days that followed.

But like other conservatives with a libertarian streak, most prominently Sen. Ted Cruz, Stickland said he was decamping for something called parler.com, a place apparently less hostile to his political persuasions but hardly a stranger to mob-think.

I dont know much about Parler. A brief stroll suggested it wont be a regular stop. I do know a thing or two about Twitter, and Stickland is partly right. Whatever you dont like, Twitter serves it in stinking heaps.

Mob mentality? Check. Hate speech? Check. Racism? Check. Anonymous libel? Check. Preening moralism and virtue signaling? Check and check. Trolls, bots and fake accounts pitting people in constant battle? You have come to the right place.

The problem of thinking like Stickland and Cruz and even President Donald Trumps reelection campaign is that it casts the social media problem as a political one. Twitter is becoming too liberal or too intolerant of conservatives, or so goes the argument.

But this isnt a conservative or liberal problem. This is a human social problem now, and one we better figure out how to fix fast, because it is giving us a political culture that promotes the worst, scares away the best and tears just about everything it gets in its maw to pieces.

Stickland isnt an interesting politician. A stock character from tea party central casting, he has consistently and successfully worked at making a joke of his office and its duty to legislate. Except for his habit of crippling good bills, his fellow conservatives stopped taking him seriously years ago.

But his social media situation is instructive as to what Big Techs platforms are doing to our national conversation and to why we cant fix social media the way it appears we are going to try.

The way things are going, free speech is going to be diminished if we let the platforms get their way. And, in the short term at least, conservatives will probably get the brunt of it.

In the long run, though, we are in danger of turning over the decision of what speech is and is not acceptable to profit-driven companies that do all they can to keep us glued to our screens.

Lets look at how this is playing out and why we need to stop it.

Last week, Facebook undisputed king of all social media had to face the music of a civil rights audit it paid for that found the platform is not sufficiently attuned to the depth of concern on the issue of polarization and the way that the algorithms used by Facebook inadvertently fuel extreme and polarizing content.

Instead of enabling free speech, Facebook privileges certain voices over less powerful voices, the auditors wrote.

The answer, according to the audit, is to somehow neutralize or disempower extreme and polarizing content issuing from privileged voices.

If that sounds like a good solution, recognize that you can put a lot of ideas and voices into those categories, and what constitutes extreme and polarizing shifts with the winds.

The solution that Facebook appears to be driving at is to remove content that might concern some people even as its removal concerns others. In response to the audit, Facebook has already removed posts and pages associated with Trump political operative turned felon Roger Stone and the far-right Proud Boys group.

Thats low-hanging fruit. And even that has been controversial. It will only get harder to parse what does and does not constitute hate speech or polarizing speech. Revolutionary Thomas Paine and abolitionist William Lloyd Garrison were polarizing, after all.

If we leave it to social media platforms to decide what is and isnt acceptable, we will only continue to be damaged as a democracy.

Even if it were possible for these companies to perfectly judge what should and shouldnt be posted (and it isnt), they have proved over time that this is not something they are going to do. As Shoshana Zuboff details exquisitely in her crucial book The Age of Surveillance Capitalism, these companies have acted at every turn to create products that deceive and divide in the name of profit.

Conservatives are hurting their own cause in this case. Cruz has been outspoken on the matter. But his instinct is toward libertarianism and preventing platforms from policing speech in any way. When he joined Parler, he said, the platform gets what free speech is all about.

That is a self-defeating strategy. Preaching to the choir gets awfully dull, and Cruz has hardly given up Twitter where his audience is larger and he gets in the sparring he seems to cherish.

If things continue on the path they are going, conservatives will have much to worry about when it comes to social medias selection of what is and isnt acceptable speech.

But they would be wise to join those on the left who post-Russian electoral interference still have a strong appetite for reining in the way America regulates platforms. And they had better act fast, before the entire left recognizes the advantage that is about to come its way from social medias big self-correction.

For too long, these companies have enjoyed freedom from liability for what people post on their sites even as their products have damaged our democracy. The wise legislator is coming to understand how that carte blanche has narrowed and cheapened the internet, when it was supposed to broaden and democratize it.

There has to be a reconnection to responsibility for what goes up that is governed the way we have always governed speech through threat of libel.

Would it substantially change the way platforms function? Of course.

Would that be what the country needs?

Take a run through Twitter today and answer that question for yourself.

Rudolph Bush is deputy editorials editor for The Dallas Morning News.

Continue reading here:

Commentary: Conservatives will defeat themselves if they don't wake up to social media reform - The Daily World

The Revolutionary Life of Paul Robeson: Scholar Gerald Horne on the Great Anti-Fascist Singer, Artist, and Rebel – The Intercept

As Donald Trump campaigns for reelection, he is increasingly sounding like a fanatical Cold War relic, railing against the communists, anarchists, and socialists while pledging to protect the real Americans from this growing Red Menace. This week on Intercepted: As Trump vows to smash leftist movements, we take a comprehensive look at the life of the revolutionary Black socialist, anti-fascist, and artist Paul Robeson. University of Houston historian Gerald Horne, author of Paul Robeson: The Artist as Revolutionary, discusses Robesons life from his early years to his time in Europe on the brink of a fascist war. The son of an escaped slave, Robeson rose to international fame as a singer and actor, but committed himself to the liberation of oppressed people across the globe and was a tenacious fighter for the freedom of Black people in the U.S. Robeson was heavily surveilled by the FBI and CIA, dragged before the House Un-American Activities Committee, and was stripped of his passport by the U.S. government.

Audio of Robesons testimony at the House Un-American Activities Committee, used throughout this episode, is a dramatization by actor James Earl Jones in the stage play, Are You Now or Have You Ever Been?

Sean Hannity: Joining us now on the phone is President Donald Trump from the White House tonight. Mr. President, thank you, sir, for being with us.

Donald Trump: Well, thank you very much. And how good is Mark?

[Sounds of toilet]

SH: I want to start Um, Mr. President? We have an election in 117 days, Mr. President, and

DJT: I actually took cognitive tests.

SH: Ok.

DJT: Very recently when I proved I was all there because I aced it. I aced the test

SH: You know

DJT: in front of doctors and they were very surprised. They said thats an unbelievable thing. Rarely does anybody do what you just did.

SH: What is your second term agenda?

DJT: Our country will suffer. Our stock markets will crash. Cases all over the place. People dying.

SH: Thank you for your time. We appreciate you being with us. And 117 days to go. Alright.

DJT: Thank you very much, Sean. Thank you.

[Musical interlude]

Jeremy Scahill: This is Intercepted.

[Musical interlude]

JS: Im Jeremy Scahill, coming to you from my basement in New York City. And this is episode 138 of Intercepted.

Catherine Herridge [CBS]: Why are African Americans still dying at the hands of law enforcement in this country?

DJT: And so are white people. So are white people. What a terrible question to ask. So are white people more white people by the way.

JS: The United States is in the midst of a period of great reckoning. While many major media outlets have moved on in their coverage, demonstrations for racial justice and Black Lives continue in cities and towns across this country.

Protesters: George Floyd! Say his name! George Floyd! Say his name! George Floyd!

JS: At the same time, the pandemic is continuing its carnage, due in no small part to the criminal incompetence of President Donald Trump. While Wall Street celebrates its gains and basks in the perceived contradictions, workers across this country are suffering. Millions of people are at risk of losing or already have already lost their employer-based health care. The paltry means-tested so-called economic stimulus was at its inception an inadequate bandaid, and now the wounds on working families are becoming infected. At the same time, the billions doled out to corporations are shrouded in unaccountability and secrecy.

And, as Trump campaigns for re-election, he is increasingly sounding like an early Cold War fanatic, railing against the communists, anarchists, socialists while pledging to protect the real Americans from this growing Red Menace.

DJT: We are now in the process of defeating the radical left, the marxists, the anarchists, the agitators, the looters, and people who, in many instances, have absolutely no clue what they are doing.

JS: In these times, the long shadow of history stretches over us all. And in thinking of the magnitude of the current world and national crisis, Ive found myself reading books, watching films, listening to music that was produced during times of crisis and struggle throughout history.

[Water Boy sung by Paul Robeson plays.]

Paul Robeson: [Singing] Water boy, where are you hiding? If you dont come, Im going to tell your Mamie.

JS: One of the great stories of the past century is that of the life of Paul Robeson. He was born in New Jersey to a father who escaped slavery. He was an athlete, a lawyer, an actor, and a singer. And his songs propelled him to international fame beginning in the late 1920s and early 1930s.

But Paul Robeson represented something much bigger than his art or his biography. His ascent to fame came as the world was in upheaval, the market crash and the Great Depression, the rise of fascist forces in Europe, and the grinding oppression of Jim Crow America. Robeson spent many of his prime years living outside the United States. He said he felt more free as a Black artist abroad than he did in the land of his birth. He traveled the world performing in the great concert halls and theater venues of Europe and beyond. He was enamored of the Soviet Union and the great hope that he placed in the liberation of Black people from the shackles of colonialism in Africa. He mastered several languages, among them German and Russian, and he gave in London what is to this day considered to be one of the greatest performances of Othello ever staged.

Paul Robeson reciting Shakespeares Othello: Soft you, a word or two before you go. I have done the state some service, and they knowt. No more of that. I pray you, in your letters, when you shall these unlucky deeds relate, speak of me as I am. Nothing extenuate, nor set down aught in malice.

JS: Paul Robeson was an international man of resistance, of worker solidarity, and he was a proud Marxist. He could have lived a life of extreme comfort and luxury. He could have chosen to just be an artist. But at his core, Paul Robeson believed that the struggle to liberate workers across the globe and to overthrow the tyranny of fascists was connected to the liberation of Black people in the United States. And when Robeson was outside of the U.S. or inside of it, he always spoke with an international perspective. After visiting with coal miners in the Welsh valley in the U.K. in the 1950s, Robeson described his political evolution in a radio interview on KPFA.

PR: And I went down in the mines with the workers and they explained to me that Paul, you may be successful here in England, but your people suffer like ours. We are poor people. And you belong to us, you dont belong to the bigwigs here in this country. And so I today feel as much at home in the Welsh valley as I would in my own Negro section in any city in the United States. And I just did a broadcast by transatlantic cable to the Welsh valley a few weeks ago. And here was the first understanding that the struggle of the Negro people, or of any people, cannot be by itself. That is, the human struggle. And so I was attracted then to met many members of the Labor Party and my politics embraced also the common struggle of all oppressed peoples, including especially the working masses, specifically the laboring people of all the world. And that, that defines my philosophy. Its a joing one of, we are a working people, a laboring people the Negro people. And theres a unity between our struggle and those of white workers in the South. Ive had white workers shake my hand and say, Paul, were fighting for the same thing. And so this defines my attitude toward socialism, and toward many other things in the world. I do not believe that a few people should control the wealth of any land, that it should be a collective ownership.

JS: Today on the show, we are going to take a journey through the life and times of Paul Robeson. From his early years to his rise to fame, to his time in Europe on the brink of a fascist war. We will hear how Robeson traveled to the frontlines of the war against General Franco to perform for the international anti-fascist brigades. Well hear of the FBI investigations, Robesons appearance before the House Un-American Activities Committee and of how Paul Robeson was stripped of his passport by a U.S. government afraid that he would become a Black Stalin.

Our guest for todays program is the historian and scholar Dr. Gerald Horne. He currently holds the John J. and Rebecca Moores Chair of History and African American Studies at the University of Houston. He is a prolific author and among his works is the recent book Paul Robeson: The Artist as Revolutionary. Dr. Hornes newest book, just published, is The Dawning of the Apocalypse: The Roots of Slavery, White Supremacy, Settler Colonialism, and Capitalism in the Long Sixteenth Century. Dr. Gerald Horne, thank you so much for joining us here on Intercepted.

Gerald Horne: Thank you for inviting me.

JS: As weve watched these events unfold over the past months, not just with the pandemic, but centrally with the uprisings that weve seen around the country in the aftermath of the killing of George Floyd, I found myself thinking a lot about Paul Robeson.

Dramatization by James Earl Jones as Paul Robeson: Is that when I am abroad, I speak out against injustices against the Negro people in this land. That is why Im here. Im not being tried for whether Im a communist. Im being tried for fighting for the rights of my people, who are still second class citizens in this country, in this United States of America. My father was a slave. I stand here struggling for the rights of my people to be full citizens in this country. And they are not.

JS: Paul Robeson was a militant anti-fascist, a radical thinker, and in your book on him, you say that he was the forerunner to Malcolm X and Martin Luther King, and that in studying his life we can understand better this history that we all continue to live through. For people that are not familiar, just give an overview of why you put Paul Robeson in that historical context.

GH: Well, Paul Robeson was born in New Jersey in 1898, passes away in Philadelphia in 1976. In between, he was a star scholar at Rutgers University, one of the few Black Americans admitted to that state school. He was also an All-American football player and a baseball catcher. He also attended Columbia University Law School and practiced law for a while. But it was soon revealed and discovered that he had a marvelous singing voice.

PR: [Singing] I dreamed I saw Joe Hill last night, alive as you and me. Says I, But Joe, youre ten years dead. I never died says he, I never died says he.

GH: And he quickly transferred to being a star concert singer and a star of the stage, and ultimately film.

PR: Lord God of Abraham, Isaac and Israel.

GH: From the 1920s up through the late 1930s, he was actually in exile. He lived in London. And there he came into contact with many anticolonial leaders. But a turning point in Paul Robesons life comes in the early 1930s, when he comes face to face with fascism as its rising in Germany. And his transition to becoming this stellar anti-fascist activist is assisted in no small measure by his good friend, another Black lawyer, speaking of William Patterson, who went on to spearhead the defense of the Scottsboro Nine in the 1930s. Recall these are the nine Black youth in Alabama who are accused falsely of sexual molestation of two Euro-American women. Their case becomes a cause clbre all over the world. Its not unlike the antiapartheid movement, which in the 1980s and 1990s becomes an international movement. And in fact I argue that the Scottsboro Nine, in some ways, was a precursor and necessary prelude to the eruption of the anti-Jim Crow movement in the 1950s in the United States of America.

In any case, Paul Robeson becomes an advocate of socialism. He visits the Soviet Union early on. The turning point, in a sense, in Paul Robesons life comes with the dawning of what London would call World War II, that is to say 1939. And he felt that with his family he might be caught in the midst of a war so he decided to return to the land of his birth. And for a while it seemed as if he was in accord with main political trends in the United States after all. But alas, with the end of World War II, you see the rise of the Red Scare, the Cold War. Robeson quickly becomes persona non grata. A turning point again in his star-crossed life comes when he confronts President Harry Truman in the White House, when Mr. Robeson is campaigning against lynching the extrajudicial murder of Black Americans, non unlike what befell George Floyd in Minnesota in May 2020.

PR: A very broad committee went in to protest the lynchings of the Negro boys in the South. He said that it wasnt politically expedient to do anything about lynching.

GH: And as Mr. Truman was being berated by Mr. Robeson, therein you can espy the onset of the decline of Mr. Robeson. He quickly becomes blacklisted. He becomes an early victim of McCarthyism. He still has a certain kind of contact with the emerging civil rights movement. I mean, for example, he rubs shoulders with Malcolm X while in London. He confers with Dr. Martin Luther King and some of Dr. Kings representatives. But its fair to say that the final decade of his life is spent generally in seclusion and he passes away in Philadelphia in early 1976.

JS: As Robeson discovers his gift for the performance arts, particularly singing and acting in the United States, and he is given some early opportunities to perform in the plays of Eugene ONeill, what was Robesons life like as he entered entertainment? And ultimately what brings him then to Europe?

GH: After leaving Rutgers, he enrolls in law school and is well on his way to becoming a well-paid lawyer. But like many people, that is to say many Black people in particular, he felt that his individual success was insignificant compared to the kind of relentless Jim Crow and mindless lynching that his people were being subjected to. But, as suggested, he left that particular life and that particular career. And then, in the early 1920s, moving to London on the premise, which proved out, that there would be more opportunities in London for a Black performer than in the land of his birth.

While in London, hes exposed to a number of radical intellectuals when Britain was considered to be a so-called top dog in the imperialist and capitalist world. That process led to the creation of a number of leading anti-fascist, anti-imperialist intellectuals. And this kind of environment influenced Robeson quite deeply and, as suggested, along with his trip to Germany as fascism was being born, helped to move him decisively to the left.

PR: I would say that, unquestionably, I am an American. Born there. My father slaved there. Upon the backs of my people was developed the primary wealth of America. The primary wealth. Theres a lot of America that belongs to me yet, you understand? But just like a Scottish-American is proud of being from Scotland, Im proud for being African. Now in our school books they tried to tell me that all Africans were savages until I got to London and found that most Africans that I knew were going to Oxford and Cambridge and doing very well and learned their culture. So I would say today that Im an American who is infinitely prouder to be of African descent, no question about it, no question about it. Im an Afro-American and I dont use the word American ever loosely again.

JS: In 1934, he travels to Moscow for the first time and Robeson said that, Through Africa I found the Soviet Union. Talk about how that first trip to the Soviet Union really profoundly changed Robesons trajectory.

GH: Well, you know, I find that people in the United States, at least certain elites and certain folks who dont know better, theyve really been able to convince Black people in the United States that everybody hates us. You go anywhere in the world, they dont like Black people. Which, of course, sort of lets U.S. Jim Crow and U.S. apartheid off the hook, lets U.S. white supremacy off the hook because the U.S. is just reflecting these global trends. But of course you dont have to be a historical materialist to recognize that these anti-Black attitudes come out of a particular cultural and historical context.

And if you look at Russia, in particular, a European country that, I think its fair to say, that was not as avid a participant in the African slave trade as some of its Western European counterparts including England and France and Portugal and Spain most notably and not only that but the man whos considered to be the founder of the modern Russian language, speaking of Pushkin, was of partial African descent himself and still is seen as a hero today.

Then theres the rather pragmatic political point, which is that the Soviet Union, at that time, needless to say, was being encircled by a number of antagonists, including imperial London, including imperial France, including Germany. So there was a pragmatic reason for Moscow to try to win favor amongst the colonial subjects of its antagonists. Not to mention those who were victimized by bigotry and racism and white supremacy in the United States of America.

There were many good reasons and many sound historical reasons for Moscow to open its embrace to Robeson. It helped to solidify his already growing attraction to the ideas of socialism. And of course he was not alone in this. This circle included many of the Black intellectuals of that time and this pro-Moscow, pro-socialist attitude is not unusual because Black people were looking for allies against U.S. imperialism and white supremacy. Just like by June 22, 1941, when Germany invades the Soviet Union, the United States is looking for allies. Which is why you have this rapid turn about in the United States of America with regard to its opinion of the Soviet Union. Joseph Stalin becomes man of the year according to Time magazine. You have Hollywood producing pro-Soviet movies, which I think you can still find on YouTube.

[Mission to Moscow clip plays.]

Mr. Davies: I believe, sir, that history will record you as a great builder for the benefit of mankind.

Stalin: It is not my achievement, Mr. Davies. Our five-year plans were conceived by Lenin and carried out by the people themselves.

Mr. Davies: The results have been a revelation to me. I confess I wasnt prepared for what I found here. You see, Mr. Stalin, Im a capitalist as you probably know.

Stalin: Yes, we know youre a capitalist. There can be no doubt about that.

GH: Which presents a vision of the Soviet Union which contrasts with the pre-World War II and post-World War II approach. And of course we all know that after the war ends, these Hollywood creators are then dragged to Washington and grilled as to why they made these pro-Soviet movies.

Newsreel: Investigating alleged communism in Hollywood, the Washington Committee on Un-American Activities has been hearing the testimony of prominent film personalities.

Eric Johnston: The motion picture industry has been accused of putting subversive and un-American propaganda on the screen. We deny that without any reservation. The pictures themselves are complete proof of its falsity.

GH: Of course, the answer was that Franklin Delanoe Roosevelt suggested that this was a good idea in order to massage U.S. public consciousness so that the U.S. population would be more prone to go along with this alliance with the Soviet Union against imperial Tokyo and fascist Berlin.

And so Robeson was part of that overall political environment. The difference is, is that after 1945, the U.S. did a 180 degree reversal with regard to its pro-Soviet attitudes. Robeson chose not to, not least because the Soviets were still supporting African liberation movements. Now this rather simple political historical understanding, its oftentimes difficult for whatever reason for many of our friends in the United States to grasp.

PR: For the first time, as I stepped on Soviet soil, I felt myself a full human being a full human being. So its unthinkable for me today that colored peoples in any part of the world would ever join a war or attacks upon the Soviet Union. Im an anti-fascist and I would feel perhaps that any war against the Soviet Union would be a fascist war. Why not talk about peace and friendship with the Soviet people.

Journalist: What are your political opinions? Have they been changed today?

PR: My political opinions about the Soviet Union have only been deepened. As I said, in the Soviet Union, Im a believer in socialism and I would say with Dr. Du Bois that I believe that the socialist lands, in the sense of the Soviet Union, China, and the peoples democracies are the hope can I repeat it? the hope for the future.

JS: Part of history that I think is so vital that people understand but its almost never talked about, is the Spanish Civil War that preceded Hitlers war of conquest and genocide throughout Europe and eventually extending elsewhere. But you had, from the United States just as an example, three thousand people who signed up under the auspices of the Abraham Lincoln Brigade people who were communists or anarchists, socialists that went to Spain to fight against the rise of fascism. And, in fact, the United States officially declared itself to be neutral. And as you write about, Paul Robeson himself goes to the frontlines in Spain to perform for the anti-fascist forces that really were at the vanguard of trying to prevent fascism from taking hold in Europe.

PR [Singing]: But your courageous children. But your courageous children.

JS: Talk about that episode and why Robeson decided to go to Spain to perform on the front lines for the anti-fascists.

GH: Robeson was not alone in terms of those sentiments in favor of the Republican regime in Spain that was being challenged by the ultimate victor, the proto-fascist Francisco Franco who, as you correctly suggest, was backed by the fascist powers. But not only backed by the fascist powers, Berlin not least, but also, you may recall, that Henry Ford, one of the top manufacturers, as theyre called in the United States and his eponymous automobile company is still with us. And so on the other side of the ledger, not only had Robeson, who went to Spain to sing before the beleaguered forces and troops, but Langston Hughes, who was perhaps the leading Black writer of the 20th century was also a part of that crew that descended on Spain.

And, interestingly enough, a number of Black Americans whose names sadly have been lost to history, they were sufficiently motivated to go to Spain as well because, like Robeson, they felt that if fascism could be defeated on the Iberian peninsula that that would bode well for its close cousin, Jim Crow, being defeated on these shores. And likewise, if fascism were to emerge victorious on the Iberian peninsula, this would give a shot in the arm to its close cousin, speaking of Jim Crow, on these shores. And so thats what motivated Robeson to go to Spain in the 1930s. Like his trip to fascist Germany, like his trip to the Soviet Union, this had a catalytic and a positive impact on his emerging anti-fascist consciousness and was one more factor that was pushing him steadily to the left.

JS: Yeah, I wanted to read a quote that you cite in your book from Robesons own description of why he travels to Spain to perform for the anti-fascist forces.

PR: I am deeply happy to contribute to this cause of Spanish culture and of the Basque children in particular. A cause which must concern everyone who stands for freedom, progressive democracy, and for humanity. Today, the artist cannot hold himself aloof.

JS: He said, Every artist, every scientist must decide now where he stands. He has no alternative. There is no standing above the conflict on Olympian heights since, the artist must take sides. He must elect to fight for freedom or slavery. I have made my choice. I had no alternative. When Robeson was asked why he said because, The history of the capitalist era is characterized by the degradation of my people. Put that in context.

GH: I still get chills when I hear that quote being rendered. Obviously hes referring to the origins of capitalism itself, something Ive dealt with in a number of books, including my most recent book, The Dawning of the Apocalypse, which deals with the 16th century. And as Karl Marx himself put it, capitalism comes upon the world stage dripping with blood with the blood of Africans in particular because it was the African slave trade, one of the most profitable enterprises known to humankind. As you know, the African slave trade was the precursor for bringing millions of Africans to these shores, including my ancestors, Im afraid to say. And after suffering through centuries of slavery, we were able to create conditions that led to a U.S. Civil War, culminating in 1865, and then we were then degraded by a century further of U.S. apartheid in this so-called land of liberty and land of freedom. So this is what Robeson was making reference to when he made those rather scalding comments about what was happening to Black people, what was happening to his people.

JS: Tell the story of how Robeson was impacted by the case of the Scottsboro Boys. This starts in 1931, where you have nine Black teenagers ranging in age from 13 to 19 years old who are falsely accused of raping two white women on a train.

Clarence Norris: The three of us were surrounded with a mob. They had shotguns, pistols, sticks, pieces of iron, everything. The crowd commenced to holler: Lets take these Black sons of bitches up in here and put em to a tree. I did thought that I was going to die.

JS: Maybe set the Scottsboro Boys case and Robesons response to it in context.

GH: These nine Black youth are riding trains in the middle of a collapsing economy. It was quite common for folks to hop on trains to get from a city of unemployment to a city where they hoped there would be employment. These two women are riding the train too. There are controversies and confrontations between the nine Black youth, all from Dixie, and the two women. It leads to this allegation that turns out to not to be accurate that they had sexually molested these women. What happens is that the aforementioned William Patterson, who becomes a leader of the International Labor Defense, in many ways they take up the banner of the Scottsboro Nine. They use this case to illustrate the frailties, if you like, of Jim Crow, the noxious nature of white supremacy. Because the International Labor Defense has an international network, because the Communist Party and the Communist International, headquartered in the then Soviet Union, that is to say speaking of the latter, its part of an international organization. And so when this Communist International and International Labor Defense take up this case, theyre able to generate a worldwide movement against U.S. Jim Crow.

James W. Ford: It is only the Communist Party, which day in and day out, fights for every demand and need of the Negroes in the terror-and lynch-ridden South.

GH: Because of the disadvantageous conditions that Black Americans face in the United States of America, historically Black Americans have needed international solidarity and international support to make a step forward. And fortunately that was present in the 1930s. Now, it turns out that it takes quite a bit of activism to free the Scottsboro Nine. For most of the 1930s, despite this international protest, picketing at U.S. consulates and legations and embassies all over the world, boycotts of U.S. based corporations, etc., they still spend most of the 1930s in prison. But eventually, they are not executed because they were definitely slated to be executed, which, I might say, was the fate of too many Black people, that is to say being accused falsely then either rushed to the electric chair of the gas chamber or dragged unceremoniously from the prison and lynched, that is to say murdered without due process of law. But fortunately that fate did not befall the Scottsboro Nine and it also, I should say, not only helped to give U.S. imperialism a black eye in the international community, it also helped to drive many Black people into the ranks of the U.S. Communist Party, including a number of its leaders. And certainly it was a factor in helping to bring Paul Robeson closer to the U.S. Communist Party. I should say at this point that in his testimony before the U.S. Congress in the 1950s, the interrogators said that he was a member of the U.S. Communist Party under a false flag, under a false name. He denied that. I guess because they were not expert interrogators, they did not ask him if he had been a member of the Communist Party of Great Britain, and I suspect that he was. And in any case that remains an avenue of research that has not been fruitfully explored.

Unidentified Actor as Richard Arens: Are you now a member of the Communist Party?

James Earl Jones as Paul Robeson: Oh, please, please, please.

Unidentified Actor as Richard Arens: Please answer, will you, Mr. Robeson.

James Earl Jones as Paul Robeson: What is the Communist Party? What do you mean by that?

Unidentified Actor as Richard Arens: Are you now a member of the Communist Party?

James Earl Jones as Paul Robeson: Would you like to come to the ballot box when I vote and take out the ballot and see?

Unidentified Actor as Richard Arens: Mr. Chairman, I respectfully suggest that the witness be directed to answer the question.

Unidentified Actor as Chairman Francis E. Walter: You are directed to answer the question.

James Earl Jones as Paul Robeson: I invoke the Fifth Amendment and forget it.

Unidentified Actor as Richard Arens: I respectfully suggest the witness be directed to answer the question.

JS: Robeson is in Europe and he returns to the United States not just completely in the grips of the Jim Crow politics and reign of the leaders of the time, but also the FBI begins to investigate Paul Robeson as well. His activism is escalating during this time, and you had fears among powerful white interests in the United States that Robeson was going to become possibly a Black Stalin. Explain that.

GH: Historically, many Black people have fled the United States and have found homes in Western Europe in particular. But what happens is that with the rise of fascism and Hitler and Mussolini taking over most of Europe, they are not, shall we say, as friendly to these Black exiles as previous governments had been. And so many of them end up in concentration camps. Many of them perish. And this is what Robeson feared would befall him and so he decided the better part of wisdom was to get out of dodge, which actually made good sense.

But as already noted, he comes back to the United States and the United States is in the process of shifting to antifascism, shifts out of antifascism almost simultaneously with the signing of the treaty of surrender on the battleship Missouri in September 1945, as Japan surrenders. And then what happens is that this is taking place at a time when the United States is still officially a Jim Crow country. Its still an apartheid country. The United States is a rigorously segregated society. But the flipside of that is that in some ways this hands the Black community on a silver platter to those who profess antiracism, which was quite unusual at the time. And so what happens is that Robeson has a certain modicum of popularity in the Black community. And this is at a time, too, when the left had not been purged from leadership of unions. Robeson in many ways was the titular leader, not only of the Black radical, or even Black progressive movement, but in some ways, a leader of the U.S. progressive movement as well. And it was felt by those who majored in hysteria that somehow this would catapult him into a leadership role in Washington where he would become the so-called Black Stalin that is ruling the United States, subjecting his political antagonists to labor camps and even worse. And this was part of the hysteria that gripped the United States at that moment. What unfolds is this rather adroit maneuver by U.S. ruling circles whereby those with foresight and vision, such as Robeson, Du Bois, et. al., are marginalized and, to a degree, are isolated. And at the same time you have this attempt to erode Jim Crow, per the Brown vs. Board of Education Supreme Court decision of 1954 saying that U.S. apartheid now is unconstitutional. And so you have this anomaly where Black people somehow, at least on a formal level, procedural level, get the right to eat in restaurants that they had been barred from, but because of the weakening of progressive unions and most Black people are working class and survive and are able to thrive because of being part of unions but because of the weakening of unions, they dont have the money to pay the bill at the restaurant.

JS: We are speaking to Dr. Gerald Horne of the University of Houston. In a moment, were going to continue this conversation by taking a look at the U.S. governments investigation of Paul Robeson during the Red Scare period as the Cold War was intensifying. Stay with us.

Read more:

The Revolutionary Life of Paul Robeson: Scholar Gerald Horne on the Great Anti-Fascist Singer, Artist, and Rebel - The Intercept

Cloud Computing in Healthcare Market 2020 Top Trend, Size and Growth, Key Insights, Segmentation, Key Regions and Future Forecast 2025 – 3rd Watch…

Global Market for Cloud Computing in Healthcare is expected to witness a stellar growth in coming few years. The market is expected flourish due to emergence of several fashion trends all across the globe. This has been a key reason of introducing Cloud Computing in Healthcare industry. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Cloud Computing in Healthcare market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the market in terms of both revenue and volume.

Get sample copy of Cloud Computing in Healthcare Market [emailprotected] https://www.adroitmarketresearch.com/contacts/request-sample/1091

This is a latest report on Cloud Computing in Healthcare market covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. This report provides latest insights about the markets drivers, restraints, opportunities, and trends. It also discusses the growth and trends of various segments and the market in various regions. The global Cloud Computing in Healthcare market is relied upon to develop generously and succeed in volume and value during the predicted time period.

Top Leading Key Players are:

McKesson Corporation, Allscripts, NextGen Healthcare, Epic Systems Corporation, Healthcare Management System, eClinicalWorks, CPSI, Computer Sciences Corporation, and many more.

Read complete report with TOC @ https://www.adroitmarketresearch.com/industry-reports/cloud-computing-in-healthcare-market

The Cloud Computing in Healthcare Market Report Serves As A Vital Guide In Portraying Current And Forecast Industry Statistics:

1. The report gives a large-scale exploration of market dynamics and factors manipulate the growth of the global Cloud Computing in Healthcare market.2. The supply/demand situation, gross margin view and competitive profile of top players are presented.3. The forecast study on the industry will be useful for business plans and growth analysis.4. Furthermore, a complete analysis of existing and emerging market segments is provided.

Global Cloud Computing in Healthcare market is segmented based by type, application and region.

Based on Type, the market has been segmented into:

by End Use (Hospitals, Diagnostics and Imaging Centres, Ambulatory Centres, and Others)

In terms of geographical segmentation, the global Cloud Computing in Healthcare market is divided into five major regional segments. These regions are Asia Pacific, North America, Latin America, Middle East and Africa and Europe.

Unveiling the geographical penetration of the Cloud Computing in Healthcare market:

1. The report consists of information related to the geographical landscape evaluating the industry into various regions.2. Crucial data consisting of market share accumulated by every region, in association with sales of every region registered is mentioned in the report.3. The valuation conducted by each region in the base year as well as the growth rate over the predicted time period is mentioned in the report.

Key Features of Cloud Computing in Healthcare Research Report:

1. This report provides detail analysis of the market and has a comprehensive understanding of the Cloud Computing in Healthcare and its commercial landscape.2. Learn about the various market strategies that are being adopted by leading companies.3. It provides a five-year forecast assessed based on how the Cloud Computing in Healthcare is predicted to grow.4. It provides insightful analysis of changing competition dynamics and keeps you ahead of competitors.5. To understand the future scope and outlooks for the Cloud Computing in Healthcare.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/1091

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

Continued here:

Cloud Computing in Healthcare Market 2020 Top Trend, Size and Growth, Key Insights, Segmentation, Key Regions and Future Forecast 2025 - 3rd Watch...

Downstream Processing Market The Biggest Trends to Watch out for 2018-2026 – Kentucky Journal 24

Market Scenario

Global Downstream Processing Marketwas valued US$ 10.46 Bn in 2017 and is expected to reach US$ 32.88 Bn by 2026, at a CAGR of 15.39 % during a forecast period.

The downstream processing market is segmented into technique, product, application, end-user, and region.

In terms of technique, downstream processing market is segmented into purification, solid-liquid separation, clarification & concentration. Based on product segment, downstream processing market is classified into chromatography columns and resins, filters, membrane adsorbers, single-use products, and other products. Further application, downstream processing market is divided into monoclonal antibody production, vaccine production, insulin production, immunoglobulin production, erythropoietin production, and other applications. In terms of end-user, downstream processing market is classified into biopharmaceutical manufacturers, and contract manufacturing organizations.

Based on regions, the global downstream processing market is divided into five main regions are North America, Europe, Asia-pacific, Latin America and Middle East & Africa.

Global Downstream Processing Market

On the basis of product, the chromatography columns and resins segment accounted for the largest share of the downstream processing market. Columns and resins are the most important component of a chromatography system and are extensively used in the separation, recovery, and purification of components of a bioactive sample. The constant need for newer and different types of columns and resins is likely to fuel market growth.

Based on application, Antibodies are one of the most predominant modalities offered by the biopharmaceutical industry today. Moreover, as antibiotic resistance is on the rising, there is an increase in demand for the development of antibodies that act against resistant strains. This, in turn, is increasing the demand for downstream processing for antibody production at industrial scale.

Request for Report Sample: https://www.trendsmarketresearch.com/report/sample/11395

The rapid growth of the biotechnology sector is one of the key trends boosting the demand for downstream processing market. This is majorly due to the high adoption of biotech processes in the pharmaceutical, agricultural, and bio-services industries. In addition, developments in the field of gene therapy and genetic engineering are estimated to propel the market during the forecast period.

The high cost of instruments used in downstream processing is expected to restrain the growth of the market.On the other hand, patent expiration of blockbuster biopharmaceutical products represents significant growth opportunities for the key players in the downstream processing market.

In terms of region, North America is expected to account for the largest share of the global downstream processing market, followed by Europe. North America is the worlds largest pharmaceutical market and a leader in biopharmaceutical research. Rising quality requirements have emphasized the need for advanced bioproduction technology in this region.

Key players operating in global downstream processing market are 3M Company, Repligen, Boehringer Ingelheim International GmbH, Eppendorf AG, Lonza Group Ltd, Corning Corporation, Ashai Kasei, Dover Corporation and Ferner PLC.

Covid 19 Impact Analysis@ https://www.trendsmarketresearch.com/report/covid-19-analysis/11395

Scope of Global Downstream Processing Market:

Global Downstream Processing Market, by Technique:

Purification Solid-liquid Separation Clarification & ConcentrationGlobal Downstream Processing Market, by Product:

Chromatography Columns and Resins Filters Membrane Adsorbers Single-use Products Other ProductsGlobal Downstream Processing Market, by Application:

Monoclonal Antibody Production Vaccine Production Insulin Production Immunoglobulin Production Erythropoietin Production Other ApplicationsGlobal Downstream Processing Market, by End-User:

Biopharmaceutical Manufacturers Contract Manufacturing OrganizationsGlobal Downstream Processing Market, by Region:

North America Europe Middle East & Africa Asia Pacific Latin America

Key players operating in Global Downstream Processing Market:

3M Company Repligen Boehringer Ingelheim International GmbH Eppendorf AG Lonza Group Ltd Corning Corporation Ashai Kasei Dover Corporation Ferner PLC

See the original post:

Downstream Processing Market The Biggest Trends to Watch out for 2018-2026 - Kentucky Journal 24

The Ascension On Cosmic Wasteland, Leaving Money On The Table – Wrestlezone

Big Kon and Vik, formerly known as The Ascension, recently spoke withWrestleZone Managing Editor Bill Pritchard and discussed various topics. The duo reflected on their WWE careers, and two highlights include their reflection on Cosmic Wasteland:

Vik: I know I was excited when we were doing that, you know, because wed already been working with Cody and Dustin quite a bit, and we enjoyed working with them. Codys quite the character and Stardust, it was something else. I know, for us, it seemed like it all fit together really well. We were working with Neville and the Luchas, and doing that, we loved that stuff. I know, personally, I did, but everything in WWE is a struggle.

Big Kon: It looked like a comic book with the six of us, and it made it exciting, it looked good, it was different characters. Cody, you know, with the Cosmic Wasteland, it looked really good visually. We worked on the entrance, and you know, Neville with them looked incredible, too, so and, of course, we can all six go, so it was a payoff. I just wished they would have capitalized on it maybe a just a little bit more.

On why WWE dropped Cosmic Wasteland before they fully capitalized on it:

Vik: I dont even know if we have the answers to that one, in that situation. I know we got left feeling kinda confused at the end of it, so I dont know. If that was, I think that was at the time, too, that kind of, if Im not mistaken, pushed Cody to leave and do what hes doing now.

Big Kon: There was a lot of money left on the table, for sure, with that one. There was money left on the table.

Vik: I mean, its just like odd how, there are so many things, like WWE you just have to fight, fight, fight, fight and sometimes I just, I dont know what the right term is, like it just, stuff gets lost.

Big Kon: Or you just, like, kick a dead horse.

Vik: Its not like were the ones kicking a dead horse, but it is, you know what I mean? And its not by performance, I would say.

The full interview is available below:

RELATED:The Ascension Reveals Their New Name, Talk About How COVID-19 Delayed Their TV Return Plans

Read the original post:

The Ascension On Cosmic Wasteland, Leaving Money On The Table - Wrestlezone

Local News: News in brief (7/18/20) – Monett Times

Those having business at the Lawrence County Judicial Center in Mt. Vernon are now required to wear masks upon entering the facility. Victim impact statements and restitution can be returned by e-mail to cvestal@lawcopa, or by regular mail to: P.O. Box 69, Mt. Vernon, MO 65712. For more information, call 417-466-2846.

The Barry County Democrats will meet at 7 p.m. on Monday, Aug. 10, at the Golden Community Center, 28686 State Hwy. J, in Golden. Members encourage local residents to vote on Tuesday, Aug. 4. For more information, call Maella Blalock at 231-343-2727.

Lawrence and Barry County Democrats will meet at 7 p.m. Thursday, July 23, at Angus Branch Steakhouse in Monett. Those wishing to dine should arrive by 5:45 p.m. Discussion will include fall activities and the Tuesday, Aug. 4 state primary election. Social distancing and the use of masks is encouraged. For more information, call Jim or Pat Kabell at 417-452-3287.

First Baptist Church of Monett, located at 2581 Highway 37, is collecting items for the Operation Christmas Child shoebox ministry. Soap, washcloths and other small items are encouraged. Toothpaste, candy and war-themed toys will not be allowed. For more information, call 417-235-7466.

Lawrence County Gospel Sing will be held from 2 to 4 p.m. Sunday, July 26, at Buck Prairie Baptist Church in Marionville. Alan Littrell will emcee the event. All singers and musicians are welcome.

The last night of the 131st Barry County Camp Meeting will be held at 7 p.m. tonight, Saturday, July 18. The event will feature Ascension Quartet in concert. The venue is located next to the Log Church, located four miles west of Butterfield on Highway U, then one-half mile south on Farm Road 1115. For more information, call 417-847-2953.

The Monett Senior Center is seeking a volunteer to deliver the Tuesday meal route each week. The deliveries typically take an hour or less to complete. For more information, call Mavis Schlessman, regional lead, at 417-235-3285 or 417-678-5383.

Sacred Heart Catholic Church, in Verona, will be hosting Vacation Bible School July 20 through July 24. For more information or to enroll, call 417-498-6054.

The Pleasant Ridge Special Road District will hold its monthly meeting in the basement of the Pleasant Ridge Baptist Church at 6 p.m. on July 20, and is open to the residents of the road district.

The Monett Area Farmers Market, sponsored by Tyson Foods, has implemented a masking policy. Service providers and servers are required to wear masks when social distancing is impossible. Customers are encouraged to wear masks as well.

Members are encouraged to attend Ozark Electric Cooperatives 84th annual meeting at Mt. Vernon High School on Friday, July 31. Members are encouraged to attend to discuss co-op business, enjoy food and receive giveaways. Registration opens at 10:30 am. Free steak sandwiches or hot dogs will be available. There will be live music by The Marks Family. Drive-thru registration will be available for those who wish to remain in their vehicles and not participate in the full meeting. While these members will still receive a $10 credit on their electric bill and a registration gift, meals will not be available in the drive-thru line. There will be parking lot shuttles along with well water testing and Mercy health checks. Participants must have a mask for the health checks.

Read more from the original source:

Local News: News in brief (7/18/20) - Monett Times

Milton teen hospitalized with COVID-19 is now walking, talking and out of ICU – Destin Log

Halene O'Connell, the 16-year-old Milton girl with COVID-19 who was clinging to life on a ventilatorjust eight daysago, has been moved out of the Intensive Care Unit and her family is "cautiously optimistic" she could soon fully recover.

Halenewas moved from the ICU to a regular hospital bed Wednesday evening after her condition improved steadily over the past week, according to her aunt, Carmen Barlianto. She had been in the ICU for a total of 18 days and on a ventilator and in a coma for 12 of those days.

RELATED: Northwest Florida teen fighting for her life against COVID-19; family begs people to wear masks

Yesterday they moved her out of the ICU, which is a huge step, Barlianto told the Pensacola News Journal in a phone interview Thursday. They did a little parade, and it was very emotional for her and my sister (Halenes mother, Carrie OConnell).

GOFUNDME FOR HALENE >>>>

Halene's medical team at The Studer Family Children's Hospital at Ascension Sacred Heart in Pensacola got a pair of red boxing gloves for Halene as a symbol of being a "COVID-19 fighter," and all of her nurses and doctors signed the gloves. She wore them as she was wheeled from her ICU bed to a regular hospital bed.

RELATED: This is a miracle: 16-year-old Florida teen hospitalized with COVID-19 gets off ventilator

She cried a lot moving to the other floor, because shes just beginning to realize all the help that its taken and the dedication from the medical staff for her fight, Barlianto said. It was a very emotional day yesterday for the whole staff, they were all crying.

Halene first began experiencing a fever and nausea on June 22, but doctors initially sent her home without testing her for coronavirus, thinking it was just a bug. However, by June 28, she couldn't even breathe while walking to the bathroom and was rushed to the children's hospital in Pensacola.

Halene's condition was "up and down" every day, according to her aunt. However, she was finally removed from her ventilator July 9and has slowly been coming out of her coma ever since. Barlianto said the teenager has startedto do things like sit up and stand for a few minutes at a timeand can walk about 10 steps before becoming too tired and weak.

She still can't text or use her cellphone, which is "hard for a 16-year-old girl," Barlianto joked.

Mentally, she's also beginning to realize what happened to her, and how close she came to not surviving.

Shes awake and coherent, but she sleeps a lot because she gets tired so quickly, Barlianto said. Shes focused on her physical therapy. Its a process. They just shared with her that she was on such a high setting on the ventilator that they were really concerned she wasnt going to make it, even with her being so young.

Doctors are also continuing to evaluate what the long-term effects of the coronavirus will be on Halene, which could take some time. For now, Halene and her mom, Carrie, who has been quarantined in the hospital with her daughter since day one, are taking things day by day and hoping toreturn home soon.

Halene's father, Robert, and sister, Hailey, haven't seen the teensince she was admitted to the hospital due to visitation restrictions.

Barlianto said the O'Connell family is floored by the outpouring of supportfrom the community and hopes Halene's story can reach all corners of the earth so people can realize what happened to her can happen to them, too. They are still reiterating their pleas for people to wear masks, social distance and wash their hands frequency.

Her story has traveled the world, and we love it. It helps us get through this, Barlianto said. Also, wear your mask. This isnt political. A lot of people maybe have gotten COVID and their symptoms arent as severe, but why even risk it because you just dont know until it hits you, and then its too late. Mask up, its not a big deal.

Annie Blanks can be reached at ablanks@pnj.com or 850-435-8632.

Go here to read the rest:

Milton teen hospitalized with COVID-19 is now walking, talking and out of ICU - Destin Log